{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-009027","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2021-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.669387+00:00","generated_at":"2026-06-30T03:49:23.984648+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Passage Bio appoints Simona King as CFO, effective August 23, 2021","bullets":["Simona King, age 49, named CFO; most recently CFO of Tmunity Therapeutics (Sep 2020–Jun 2021).","Annual base salary of $425,000, cash bonus up to 40% of base, and option for 360,000 shares.","Options vest 1/4 after one year, then monthly over 3 years; severance includes 9–12 months salary.","Bruce Goldsmith (CEO) serves as interim Principal Financial Officer until King's start date."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-009027","json":"https://secwatch.observer/filing/0001558370-21-009027.json","markdown":"https://secwatch.observer/filing/0001558370-21-009027.md","text":"https://secwatch.observer/filing/0001558370-21-009027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837021009027/0001558370-21-009027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837021009027/tmb-20210715x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T03:49:23.984648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54e5ee137b","claim":"Simona King was appointed as Chief Financial Officer at Passage BIO, Inc..","evidence_excerpt":"appointed Simona King, age 49, as Chief Financial Officer, effective on or about August 23, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837021009027/0001558370-21-009027-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"eb4e3eebc7","claim":"Bruce Goldsmith was appointed as Principal Financial Officer at Passage BIO, Inc..","evidence_excerpt":"The Board appointed Bruce Goldsmith, Ph.D., a member of the Board and the Company’s President and Chief Executive Officer, as the Company’s Principal Financial Officer, effective immediately until the Commencement Date","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837021009027/0001558370-21-009027-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}